Female Contraception - Pipeline Review, H1 2018

  • ID: 4576114
  • Drug Pipelines
  • 86 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Agile Therapeutics Inc
  • Bayer AG
  • Evofem Biosciences Inc
  • Hervana Ltd
  • MedinCell SA
  • Mithra Pharmaceuticals SA
  • MORE
Female Contraception - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Female Contraception - Pipeline Review, H1 2018, provides an overview of the Female Contraception (Women's Health) pipeline landscape.

Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization and natural methods. Contraception generally work by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization) and preventing a fertilized egg from implanting in the uterus (hormones).

Report Highlights:

This latest pipeline guide Female Contraception - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Female Contraception (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Contraception (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 5, 3, 8 and 4 respectively. Similarly, the Universities portfolio in Pre-Registration, Phase II and Preclinical stages comprises 1, 1 and 2 molecules, respectively.

Female Contraception (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Female Contraception (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Female Contraception (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Female Contraception (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Female Contraception (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Female Contraception (Women's Health)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Female Contraception (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Female Contraception (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Agile Therapeutics Inc
  • Bayer AG
  • Evofem Biosciences Inc
  • Hervana Ltd
  • MedinCell SA
  • Mithra Pharmaceuticals SA
  • MORE
Introduction

Report Coverage

Female Contraception - Overview

Female Contraception - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Female Contraception - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Female Contraception - Companies Involved in Therapeutics Development

Agile Therapeutics Inc

Bayer AG

Evofem Biosciences Inc

Hervana Ltd

MedinCell SA

Mithra Pharmaceuticals SA

Orbis Biosciences Inc

Teva Pharmaceutical Industries Ltd

Viramal Ltd

Female Contraception - Drug Profiles

(anastrozole + levonorgestrel) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(dienogest + ethinyl estradiol) PR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(drospirenone + estetrol) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(estradiol + segesterone acetate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(ethinylestradiol + segesterone acetate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AG-200 ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AG-200 SP - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AG-20015 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AG-890 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Amphora - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

drospirenone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Female Contraception - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EC-317 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EC-508 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EC-625 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etonogestrel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etonogestrel ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJ-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDC-WWM - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody Conjugates for Female Contraception - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOV-1003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OB-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PPCM - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-003296 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Female Contraception - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target Progesterone Receptor for Female Contraception - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Female Contraception - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TV-46046 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Female Contraception - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Female Contraception - Dormant Projects

Female Contraception - Discontinued Products

Female Contraception - Product Development Milestones

Featured News & Press Releases

May 03, 2018: Mithra Announces Last Subject Visit in Estelle Phase III Study in EU/Russia and Completion of Endometrial Substudy

Mar 28, 2018: Mithra Applies For Additional Estelle Patent Based On Positive Hemostasis Data

Mar 23, 2018: Mithra Announces Completion of Estelle Cycles Required In Phase Iii Contraception Studies

Jan 23, 2018: Evofem Biosciences Announces First Patient Enrolled in Phase 2b/3 STI Trial of Amphora and Expects Phase 3 Contraceptive Clinical Trial Data First Quarter 2019

Jan 03, 2018: Population Councils One-Year Contraceptive Ring Advances to FDA Review

Dec 07, 2017: MedinCell receives grant to develop long-acting injectable contraceptive

Nov 30, 2017: Mithra Provides Update On Estelle Study

Oct 30, 2017: Mithra Completes Recruitment for Estelle Phase III Study in US & Canada

Oct 30, 2017: Mithra Completes Recruitment for Estelle Phase III Study in US and Canada

Aug 18, 2017: Mithra Announces First Subject Completes Estelle Phase III Study

Aug 09, 2017: Mithra Pharmaceuticals: Recruitment Completed in Estelle Population PK Sub study

Jul 27, 2017: Evofem Biosciences Announces First Patient Enrolled in a Phase 3 Clinical Trial of AMPHORA for Prevention of Pregnancy

Jun 26, 2017: Estelle Phase IIB Results on Well-Being and Body Weight Published in Leading Peer-Reviewed journal

May 12, 2017: Mithra to Initiate PK Study for Estelle

Feb 07, 2017: Mithra Completes Recruitment For European Phase III Estelle Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Female Contraception, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Female Contraception - Pipeline by Agile Therapeutics Inc, H1 2018

Female Contraception - Pipeline by Bayer AG, H1 2018

Female Contraception - Pipeline by Evofem Biosciences Inc, H1 2018

Female Contraception - Pipeline by Hervana Ltd, H1 2018

Female Contraception - Pipeline by MedinCell SA, H1 2018

Female Contraception - Pipeline by Mithra Pharmaceuticals SA, H1 2018

Female Contraception - Pipeline by Orbis Biosciences Inc, H1 2018

Female Contraception - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018

Female Contraception - Pipeline by Viramal Ltd, H1 2018

Female Contraception - Dormant Projects, H1 2018

Female Contraception - Dormant Projects, H1 2018 (Contd..1), H1 2018

Female Contraception - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Female Contraception, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Agile Therapeutics Inc
  • Bayer AG
  • Evofem Biosciences Inc
  • Hervana Ltd
  • MedinCell SA
  • Mithra Pharmaceuticals SA
  • Orbis Biosciences Inc
  • Teva Pharmaceutical Industries Ltd
  • Viramal Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll